Rani Therapeutics - רווח החברה לפני מסים, ריבית ופחת RANI

Rani Therapeutics (RANI) is scaling B2B licensing of its robotic capsules to achieve global market capture. The current EBITDA value confirms this trend, stabilizing at 0.00. Growth is driven by alliances with industry behemoths and the replacement of injections for diabetes treatment. Meanwhile, the US-based localization of development and the humanitarian status of medicine fully shield the company's patents from geopolitical risks.

For Rani Therapeutics, which is scaling partnerships for the oral delivery of biologics, analyzing the absolute cash result of operations allows for an assessment of the real monetization efficiency of the RaniPill platform. This indicator measures the actual volume of operating cash flow before depreciation, alerting the investor to hidden liquidity contraction and capital erosion risks even before the publication of official financial statements.